HOME >> BIOLOGY >> NEWS
New Medication Means New Choices For Families Dealing With Alzheimers Disease

Hershey, Pa. -- A new study from Penn State's College of Medicine finds that when medication for Alzheimer's disease is offered to all patients, family members of patients in the early stages of Alzheimer's are the most likely to accept available treatment.

"When dealing with this terrible disease, families are faced with many extremely difficult decisions. One of those decisions is whether or not to treat their ill family member with this relatively new drug, that doesn't stop the disease, but slows the progression of the disease," says Paul Kettl, M.D., associate professor of psychiatry and acting chair of psychiatry at Penn State. Kettl is also chief of psychiatry with the Penn State Geisinger Health System in Hershey, Pa.

The results of the one-year study titled, "Family Treatment Decisions in Alzheimer's Disease," was presented today (June 3) at the American Psychiatric Association meeting in Toronto.

Kettl studied 60 patients with Alzheimer's disease who were admitted consecutively to the inpatient psychiatry unit at Hershey Medical Center. The one-year study asked families whether or not they wanted the patient to be treated with the drug donepezil or vitamin E. Both treatments do not stop the disease but significantly slow the progress of the disease. Donepezil has been widely prescribed by physicians for about a year.

"There were 28 people in the treatment group and 32 people in the non-treatment group. We found there was no difference based on age or sex," says Kettl. "The difference in treatment decisions was determined more by how far the disease had progressed. For patients who were in the early stages of the disease and often were cared for at home, families overwhelmingly chose to treat the patient. For those patients who lived in a nursing home and the disease was fairly advanced, families chose to withhold the treatment."

Kettl says these kinds of difficult ethical questions will have to
'"/>

Contact: Leilyn Perri
lperri@psghs.edu
717-531-8604
Penn State
3-Jun-1998


Page: 1 2

Related biology news :

1. Medication reconciliation, pharmacist involvement vital to reducing medication errors, study finds
2. Possible Dangers Of Taking Over-The-Counter Medications For Hepatitis C Patients
3. Common Anti-Viral Medication Prevents Severe Eye Herpes
4. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
5. Material Choices For The Chemical Industry
6. Families with severe form of bipolar disorder help scientists narrow the search for disease genes
7. Families with two or more children with autism sought for $10.2 million study
8. Sudden Cardiac Death May Run In Families
9. Vastly Different Virus Families May Be Related
10. Dealing with reams of data
11. New theory of cell death proposed in UCSB Alzheimers research

Post Your Comments:
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
Cached News: